Tata India Pharma & Healthcare IDCW Payout Direct Plan
SIP amount
Min. ₹100
Lumpsum amount
Min. ₹5,000

Tata India Pharma & Healthcare IDCW Payout Direct Plan

NAV
₹35.9776
-0.06%
(20 Nov)
AUM
1,325 Cr
TER
0.62%
Risk
Very High Risk
Insights
Total Expense Ratio (TER) is in the bottom 25% of comparable funds
Net Asset Value (NAV) is above its 200 days moving average
Asset Under Management (AUM) is in the top 25% of comparable funds
In beta. Send feedback here.
Compare with other fund
1Y
+12.3%
+12.3%
+12.2%
+12.2%
+6.1%
3Y
+30.8%
+30.8%
+31.1%
+31.1%
+24.2%
5Y
+32.7%
+32.7%
+31.2%
+31.2%
+19.6%
ALL
+12.3%
+12.3%
+16.9%
+16.9%
+13.8%
VOL
20.1%
20.1%
20.1%
20.1%
15.5%
TER
0.8%
0.8%
0.9%
0.9%
0.6%
AUM
₹5,714 Cr
₹5,714 Cr
₹1,466 Cr
₹1,466 Cr
₹1,325 Cr
INFO
0.61
0.61
0.84
0.84
0.89
Past performance
Past performance is no guarantee of future returns.
Had you invested
Over the last
1Y
3Y
ALL
Your returns would have been
Tata India Pharma & Healthcare IDCW Payout (DP)
₹1,00,00,00,000
14.0%
Fixed deposit
₹40,00,00,000
6.0%
Bank savings
₹40,00,00,000
3.0%
See fund holdings as of 31st Oct
Top holdings
Sun Pharmaceuticals Industries Ltd
9.6%
Apollo Hospitals Enterprise Ltd
5.1%
HealthCare Global Enterprises Ltd
5.0%
Lupin Ltd
4.9%
Max Healthcare Institute Ltd Ordinary Shares
4.7%
Torrent Pharmaceuticals Ltd
4.5%
Alkem Laboratories Ltd
4.4%
Abbott India Ltd
4.0%
Cipla Ltd
3.9%
Ipca Laboratories Ltd
3.6%
Top industry exposure
Healthcare
96.3%
Basic Materials
2.2%
Other information
Minimum SIP
₹100
Minimum lumpsum
₹5,000
Additional lumpsum
₹1,000
Portfolio turnover
55%
Lock-in period
-
Exit load
• 0.25% for redemption within 30 days
Fund objective
The investment objective of the scheme is to seek long term capital appreciation by investing atleast 80% of its net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in India.
Fund manager(s)
Rajat Srivastava

FAQs